MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-TN-02-0033866
Regenix Drugs Limited - healthcare in Chennai, Tamil Nadu, India. FY 2026 financials & compliance.
Revenue · FY 2024
₹177.12 Cr
▲ 9% YoY
Net profit · FY 2024
₹5.2 Cr
Net margin 2.9%
EBITDA · FY 2024
₹9.77 Cr
EBITDA margin 5.5%
Authorised capital
₹21.55 Cr
Registered with MCA
Paid-up capital
₹18.08 Cr
Issued & subscribed
Open charges
₹11.86 Cr
Satisfied ₹17.81 Cr
Company age
19 yrs
Est. 2007
Employees · EPFO
830
Provident fund records
About Regenix Drugs Limited
Data last updated:
Regenix Drugs Limited is a public limited company based in Chennai, Tamil Nadu, India. It operates in the medical equipment retail and distribution segment of the healthcare sector. It was incorporated on 10 May 2007 and has been in existence for over 19 years.
The company is registered with the Registrar of Companies (ROC), Chennai, under CIN U24232TN2007PLC063446. Its GSTIN is 33AADCR6672D1ZH (Tamil Nadu). The company holds 6 GST registrations, of which 2 are active.
The company has an authorised share capital of ₹21.55 Cr and a paid-up capital of ₹18.08 Cr. It was formerly known as Regenix Drugs Private Limited. It is led by directors including Ramamurthy Ayyavuthevar (Managing Director) and Krishanamoorthy Nirosha (Whole-Time Director).
Its last annual general meeting (AGM) was held on 22 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Jamal Sonu Terrace 42/1 Loganathan Nagar First Street 100 Feet Road Choolaimedu, Chennai, Tamil Nadu, India – 600094.
As per the financials filed for FY 2024, the company reported a revenue of ₹177.12 Cr, a growth of 9% compared to the previous year. For the same year it recorded a net profit of ₹5.2 Cr (net margin 2.9%) and EBITDA of ₹9.77 Cr (EBITDA margin 5.5%). Revenue has grown at a compounded annual rate (CAGR) of 10% over five years.
The company has about 830 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.
The company is associated with 1 brand: Uperp. As per MCA filings, the company has open charges of ₹11.86 Cr and satisfied charges of ₹17.81 Cr on record. Court records list 33 cases involving the company, including 4 filed by the company and 29 filed against it; 6 cases are pending.
Regenix Drugs Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-TN-02-0033866). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website regenix.in.
Company details
CIN U24232TN2007PLC063446
Registration Number 063446
Incorporation Date 10 May 2007
ROC Chennai
Listing Status Unlisted
Company Status Active
Date of Last AGM 22 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-TN-02-0033866
CIN history
Regenix Drugs has one previous CIN (Corporate Identification Number): U24232TN2007PTC063446. The current CIN is U24232TN2007PLC063446, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232TN2007PLC063446 | Current |
| U24232TN2007PTC063446 | Previous |
Key People
Ramamurthy Ayyavuthevar Managing Director Krishanamoorthy Nirosha Whole-Time Director Balaji Ramamurthy Whole-Time Director Recognitions & Rankings of Regenix Drugs
Contact details
Regenix Drugs Limited's registered office is in Chennai, Tamil Nadu. Its website is regenix.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressJamal Sonu Terrace 42/1 Loganathan Nagar First Street 100 Feet Road Choolaimedu, Chennai, Tamil Nadu, India – 600094
- IndustryHealthcare, Medical Equipment Retail & Distribution
To see the full contact details of Regenix Drugs Limited, buy the company report.
Comprehensive company report
Regenix Drugs Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Regenix Drugs operates one associated brand: Uperp. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Offers liquid-based cytology tests for effective cervical cancer screening. | uprepindia.com |
Business activity
The main business activities of Regenix Drugs are manufacturing and trade. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and wholesale trading. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | |
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Regenix Drugs Limited, buy the company report.
Financials of Regenix Drugs Limited
FY 2024 filings availableRegenix Drugs Limited reported revenue of ₹177.12 Cr (up 9% YoY) for FY 2024.
Revenue · FY 2024
₹177.12 Cr ▲ 9%
Net profit · FY 2024
₹5.2 Cr margin 2.9%
EBITDA · FY 2024
₹9.77 Cr margin 5.5%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 9%
5 years · compounded
▲ 10%
EBITDA CAGR growth
1 year
▲ 6%
5 years · compounded
▲ 19%
Revenue has grown at a compounded annual rate (CAGR) of 10% over five years, including 9% growth in the latest year. EBITDA rose 6% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹177.12 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹9.77 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹5.2 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 5.5% | ||||
| Net Profit Margin | 2.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Regenix Drugs Limited, buy the company report.
Board of directors of Regenix Drugs Limited
Regenix Drugs has 11 current directors and 23 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Malathi Ramamurthy | Director | 15 Apr 2012 | 14 Years 6 Months | Current |
| Ayyamperumal | Director | 26 Aug 2019 | 7 Years 2 Months | Current |
| Krishanamoorthy Nirosha Also directs: Regenix Biosciences Limited | Whole-Time Director | 21 Jun 2021 | 5 Years 4 Months | Current |
| Guhan Ramamurthy Also directs: Neuro Imagine Foundation | Director | 21 Jun 2021 | 5 Years 4 Months | Current |
| Balaji Ramamurthy Also directs: Regenix Biosciences Limited | Whole-Time Director | 01 Oct 2022 | 4 Years 1 Months | Current |
| Govindarajan Venkatakrishna Also directs: Aarthi Scans Private Limited | Director | 20 Mar 2010 | 16 Years 7 Months | Current |
Showing 6 of 11 current directors. View all directors
Peer comparison
Regenix Drugs Limited is compared with the 6 companies closest to it by revenue in the Healthcare industry (Diagnostics and Pathology Labs, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sriram Healthcare Private Limited | ₹192.28 Cr (FY 2025) | -8.0% | Kasauli, Himachal Pradesh, India | |||
| Parnax Lab Limited | ₹189.41 Cr (FY 2025) | 0.0% | Mumbai, Maharashtra, India | |||
| Goldencross Pharma Limited | ₹187.87 Cr (FY 2025) | 31.0% | Mumbai, Maharashtra, India | |||
| Comed Chemicals Limited | ₹187.35 Cr (FY 2025) | 12.0% | Vadodara, Gujarat, India | |||
| Mapra Laboratories Pvt Ltd | ₹184.45 Cr (FY 2025) | 5.0% | Mumbai, Maharashtra, India | |||
| Naxpar Pharma Private Limited | ₹183.89 Cr (FY 2025) | 1.0% | Mumbai, Maharashtra, India | |||
| Regenix Drugs Limitedthis company | ₹177.12 Cr (FY 2024) | ₹5.2 Cr | 2.9% | 9.0% | 830 | Chennai, Tamil Nadu, India |
To see the full peer comparison of Regenix Drugs Limited, buy the company report.
Auditor
Regenix Drugs Limited is audited by J.Thomas Fernando & Co for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| J.Thomas Fernando & Co | FY 2024 | 004402S |
Shareholding
The shareholding of Regenix Drugs Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Regenix Drugs Limited, buy the company report.
Charges & borrowings
Open charges
₹11.86 Cr
Satisfied charges
₹17.81 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 10 Jan 2024 | 100907370 | Hdfc Bank Limited | ₹51.17 Lakh | Open | |
| 05 Sep 2023 | 100786726 | Hdfc Bank Limited | ₹21.2 Lakh | Open | |
| 13 Jul 2020 | 100362965 | Hdfc Bank Limited | ₹10.99 Cr | Open | |
| 29 Jul 2015 | 10584550 | Axis Bank Limited | ₹14.72 Lakh | Open | |
| 17 Jul 2017 | 100111559 | Others | ₹7.99 Cr | Satisfied |
To see the full charge records of Regenix Drugs Limited, buy the company report.
Total charge records: 10 View all charges
Legal cases
Regenix Drugs Limited has 33 court cases on record: 4 filed by Regenix Drugs, 29 filed against it. 6 cases are pending and 27 are disposed.
Total cases
33
Filed by the company
4
Filed against the company
29
Pending
6
Disposed
27
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 26 | 23 | 6 |
| District courts | 7 | 6 | 0 |
Cases on record (5 of 33)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, TAMIL NADU | Appeal | Filed against the company by Bharti Life Sciences Pvt Ltd | Pending |
| High Court, TAMIL NADU | Original application | Filed against the company by Strides Arcolab Limited., and 2 others | Pending |
| High Court, TAMIL NADU | Court case (OSA) | Filed against the company by Strides Arcolab Limited., and 2 others | Disposed |
| High Court, TAMIL NADU | Civil suit | Filed against the company by Strides Arcolab Limited., and 2 others | Disposed |
| High Court, TAMIL NADU | Appeal | Filed against the company by Strides Arcolab Limited and 2 others | Disposed |
To see the full case history of Regenix Drugs Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Regenix Drugs Limited was last rated by Crisil on 28 Jan 2020.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 28 Jan 2020 |
To see the full credit ratings and regulatory alerts of Regenix Drugs Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Regenix Drugs Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
Regenix Drugs has 2 subsidiary companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
2
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Regenix Biosciences Limited | U24100TN2006PLC059065 | |
| Regenix Super Speciality Laboratories Private Limited | U85300TN2011PTC080777 |
To see the full group structure of Regenix Drugs Limited, buy the company report.
Employees & EPFO
Regenix Drugs Limited has a workforce of 830 employees on its EPFO records as of Mar 20, 2025, across 1 active EPFO establishment.
Employee count
830
Active EPFO establishments
1
Employee growth
-1.31%
GST
Regenix Drugs has 6 GST registrations: 2 active and 4 cancelled or inactive.
Total GSTINs
6
Active
2
Cancelled / inactive
4
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 33AADCR6672D1ZH | Tamil Nadu | Active | 01 Jul 2017 |
| 33AADCR6672D2ZG | Tamil Nadu | Active | 12 Mar 2020 |
To see the full GST registrations and return filing status of Regenix Drugs Limited, buy the company report.
Recent activity
Regenix Drugs Limited has 33 board changes on record since 2007: 11 appointments and 22 cessations. The latest: Radhakrishnan Venu Murali was appointed as Director on 24 Sep 2023.
Charges
A charge with Hdfc Bank Limited of Rs. 10.99 Cr registered on 13 Jul 2020 with Charge ID 100362965 was modified on 21 Jan 2025.
AGM
Regenix Drugs Limited last Annual general meeting of members was held on 22 Sep 2024 as per latest MCA records.
Filing
Regenix Drugs Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Chennai.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.51 Cr with Charge ID 100907370 was registered on 10 Jan 2024.
Appointed
Radhakrishnan Venu Murali was appointed as Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.21 Cr with Charge ID 100786726 was registered on 05 Sep 2023.
Appointed
Balaji Ramamurthy was appointed as Whole-Time Director.
Appointed
Akshay Arvind was appointed as Director.
Ceased
Ramachandran Muthukumar ceased to be Ceo(Kmp).
Ceased
Saleem Mohamed Mohamed Haniffa ceased to be Director.
Ceased
Guhan Ramamurthy ceased to be Additional Director.
Ceased
Krishanamoorthy Nirosha ceased to be Additional Director.
43 earlier events are in the company report.
Frequently asked questions
Regenix Drugs is an active public limited company based in Chennai, Tamil Nadu, India. The company works in medical equipment retail and distribution, within the healthcare industry. It was incorporated on 10 May 2007 (19+ years old) and is registered under CIN U24232TN2007PLC063446.
Regenix Drugs has 11 current directors:
- Ramamurthy Ayyavuthevar - Managing Director
- Krishanamoorthy Nirosha - Whole-Time Director
- Balaji Ramamurthy - Whole-Time Director
- Malathi Ramamurthy - Director
- Ayyamperumal - Director
- Guhan Ramamurthy - Director
- Govindarajan Venkatakrishna - Director
- Radhakrishnan Venu Murali - Director
- Gunasekaran Raju - Director
- Akshay Arvind - Director
- Srividhya - Nodal Officer
The latest financial statements of Regenix Drugs on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 22 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Regenix Drugs is 33AADCR6672D1ZH, registered in Tamil Nadu. The company has 6 GST registrations in all, of which 2 are active and 4 are cancelled or inactive. Other active GSTINs include 33AADCR6672D2ZG (Tamil Nadu).
The CIN (Corporate Identification Number) of Regenix Drugs is U24232TN2007PLC063446. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Regenix Drugs has 33 court cases on record: 4 filed by the company and 29 filed against it. 6 are pending. Most are in the high courts.
Regenix Drugs was incorporated on 10 May 2007, making it 19+ years old. It is registered with the Registrar of Companies, Chennai.
The peers of Regenix Drugs by revenue are Sriram Healthcare Private Limited, Parnax Lab Limited, Goldencross Pharma Limited, Comed Chemicals Limited, Mapra Laboratories Pvt Ltd and 1 more, all in the Healthcare industry (Diagnostics and Pathology Labs, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Radhakrishnan Venu Murali was appointed as Director on 24 Sep 2023. Balaji Ramamurthy was appointed as Whole-Time Director on 01 Oct 2022. Akshay Arvind was appointed as Director on 25 Sep 2022. Regenix Drugs has 33 board changes on record in total.
Yes, Regenix Drugs is registered as a medium enterprise under Udyam registration (number: UDYAM-TN-02-0033866).
Regenix Drugs can be reached through the website regenix.in. Its registered office is in Chennai, Tamil Nadu, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages